Table 3 Overview of those who Completed, Refused or Died during the Study
Characteristic | Completed the study N = 90 (%) | Died during study N = 15 (%) | Refused follow-up N = 7 (%) |
|---|---|---|---|
Mean age at baseline interview (SD) | 73.6 year SD (6.2) | 72.9 year SD (4.6) | 76.7 year SD (6.0) |
Sex | Â | Â | Â |
Female | 66 | 9 | 6 |
Male | 24 | 6 | 1 |
Marital status | Â | Â | Â |
Married or living common-law | 46 | 12 | 4 |
Widowed | 22 | 2 | 1 |
Separated/divorced | 18 | 0 | 1 |
Single | 4 | 1 | 1 |
No Information | 0 | 0 | 0 |
Lives alone | Â | Â | Â |
Yes | 37 | 5 | 3 |
No | 53 | 10 | 4 |
Born in Canada | Â | Â | Â |
Yes | 50 | 11 | 4 |
No | 40 | 4 | 3 |
Type of cancer/alive at end of study and completed study | Â | Â | Â |
Lung | 19/19 (100%) | 8 | 0 |
Breast | 41/44 (93.2%) | 0 | 3 |
Colorectal | 14/18 (77.8%) | 24 | 4 |
Lymphoma | 13/13 (100%) | 1 | 0 |
Multiple myeloma | 3/3 (100%) | 0 | 0 |
Extent of disease at diagnosis | Â | Â | Â |
Early (stage 0–2) | 55 | 2 | 6 |
Advanced (stage 3–4) | 35 | 13 | 1 |
Enrolled into clinical trial | Â | Â | Â |
Yes | 7 | 14 | 7 |
No | 83 | 1 | 0 |
Treatment proposed | Â | Â | Â |
Watchful waiting | 2 | 0 | 0 |
Surgery | 47 | 1 | 6 |
Chemotherapy | 29 | 13 | 0 |
| Â | 9 | 1 | 0 |
Radiation therapy Hormonal therapy | 3 | 0 | 1 |
Cancer diagnosis | Â | Â | Â |
First diagnosis | 79 | 14 | 7 |
Recurrence | 2 | 0 | 0 |
New diagnosis, not first diag. | 9 | 1 | 0 |
Ecog Performance scale at baseline | Â | Â | Â |
0 | 65 (72.2) | 2 (13.3) | 5 (71.4) |
1 | 14 (15.6) | 6 (40.0) | 2 (28.6) |
2 | 9 (10.0) | 3 (20.0) | 0 |
3 | 2 (2.2) | 4 (26.7) | 0 |
4. | 0 | 0 | 0 |
Mood impairment (HADS A or D ≥ 10) | 18 (20.0) | 7 (46.7) | 1 (14.3) |
Cognitive impairment (MMSE ≤ 26 or Moca ≤ 26) | 3 (3.3) | 3 (20.0) | 2 (28.6) |
IADL disability (OARS) | 27 (30.0) | 8 (53.3) | 4 (57.1) |
ADL disability (Katz) | 7 (7.8) | 4 (26.7) | 1 (14.3) |
Mean number of self-reported comorbid conditions (Functional comorbidity Index) | 2.0 (SD 1.9) | 3.3 (SD 2.5) | 1.9 (SD 1.2) |